In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival

समान संसाधन

• Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
  द्वारा: Brave, SR, और अन्य
  प्रकाशित: (2011)
• A secondary RET mutation in the activation loop conferring resistance to vandetanib
  द्वारा: Takashi Nakaoku, और अन्य
  प्रकाशित: (2018-02-01)
• A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
  द्वारा: Pacey, S, और अन्य
  प्रकाशित: (2016)
• Deciphering the resistance mechanism of RET kinase mutant against vandetanib and nintedanib using molecular dynamics simulations
  द्वारा: Guodong Zheng, और अन्य
  प्रकाशित: (2021-12-01)
• Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
  द्वारा: Fallahi P, और अन्य
  प्रकाशित: (2019-08-01)